Professor Pier Lambiase

About Professor Pier Lambiase

Professor Pier Lambiase is a leading London consultant cardiologist who specialises in the treatment of heart rhythm disorders and pacemaker implantation. He graduated from Oxford University in 1992 and trained in cardiology at St Thomas’ and Hammersmith Hospitals. Following completion of a PhD in 2002, Professor Pier Lambiase won the British Cardiovascular Society Young Investigator Award and the Michael Davies Early Career Research Award in 2016. Between 2002-2004 he completed clinical cardiology training at St Thomas’ specialising in arrhythmia treatment (electrophysiology) and pacemakers & defibrillators. He undertook his higher specialist training in electrophysiology and was appointed as a consultant cardiologist and senior lecturer at UCL in 2006 being promoted to Professor in 2015. He currently runs a nationally recognised clinic that researches into the causes of cardiac arrest and treatment of inherited rhythm disturbances and SADS (Sudden Arrhythmic Death Syndrome) at Barts Heart Centre. Professor Pier Lambiase has co-written national and international guidelines on the treatment of arrhythmias and prevention of sudden death. He has published over 400 peer-reviewed papers in cardiology. He is an editor of the Oxford Handbook of Inherited Cardiovascular Disease sits on the editorial board of a number of specialist journals including the European Heart Journal. He leads a research group studying rhythm disturbances funded by the British Heart Foundation including a randomised controlled clinical trial on the treatment of atrial fibrillation in heart failure (CRAAFT HF) and testing novel devices which stimulate the nerves supplying the heart (neuromodulation) to prevent rhythm disturbances. He pioneered the use of subcutaneous cardiac defibrillator (S-ICD) leading an international registry (EFFORTLESS). He developed a sudden death risk prediction algorithm for Brugada Syndrome utilising European and Brazilian datasets. His collaborative studies in cardiac devices have involved the APPRAISE ATP, PRAETORIAN trials with US & European centres published in NEJM, JAMA, JACC and Circulation.